Vanguard Fiduciary Trust
BIAF icon

Vanguard Fiduciary Trust’s bioAffinity Technologies BIAF Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Hold
31,071
– – ﹤0.01% 3964
2026
Q1 		$119K Buy
+31,071
New +$50.2K ﹤0.01% 3675

Other funds holding BIAF

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust's BIAF Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its bioAffinity Technologies (BIAF) position steady in Q2 2026 at 31,071 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Vanguard Fiduciary Trust first reported a position in BIAF in Q1 2026 and has held it in 2 quarters since. The position peaked at $119K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Vanguard Fiduciary Trust held 31,071 shares of bioAffinity Technologies worth $25.2K as of Q2 2026.
  • Vanguard Fiduciary Trust left its bioAffinity Technologies share count unchanged in Q2 2026.
  • bioAffinity Technologies made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3964 holding.
  • Vanguard Fiduciary Trust first reported a position in bioAffinity Technologies in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's bioAffinity Technologies position peaked at $119K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.